Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylphenidate and physical activity for cancer-related fatigue in metastatic cancer patients on anti-PD1 immunotherapy
NCT03525873Phase 3Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2018
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of methylphenidate hydrochloride extended-release chewable tablet in cancer-related fatigue (CRF) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Functional Assessment of Chronic Illness Therapy-Fatigue at 12 weeks. Started Aug 2018; status: active, not recruiting.
02
Drugs
methylphenidate hydrochloride extended-release chewable tablet
03
Conditions
cancer-related fatigue (CRF)
Beyond the preview
Go deeper on NCT03525873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03525873.